Ticagrelor and prasugrel are independent predictors of improved long‐term survival in ACS patients. (9th September 2020)

• Record Type: Journal Article
• Authors: Gager, Gloria M.; Jilma, Bernd; Winter, Max‐Paul; Hengstenberg, Christian; Lang, Irene M.; Toma, Aurel; Prüller, Florian; Wallner, Markus; Kolesnik, Ewald; von Lewinski, Dirk; Siller‐Matula, Jolanta M.
• Is Part Of: European journal of clinical investigation. Volume 50:Number 11(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-09-09
• Subjects: clopidogrel -- MEA -- mortality -- platelets -- prasugrel -- ticagrelor; Pathology -- Periodicals; Medical research -- Periodicals; 616.075
• DOI: 10.1111/eci.13304
• Languages: English
• ISSNs: 0014-2972

Abstract

Abstract: Aim: To investigate the long‐term clinical benefit of dual antiplatelet therapy with potent P2Y12 inhibitors compared to clopidogrel in patients with acute coronary syndrome (ACS). Methods: In this prospective multicenter observational study, we enrolled 708 patients with ACS treated with clopidogrel (n = 137), ticagrelor (n = 260) or prasugrel (n = 311). Major adverse cardiac events (MACE; over 1 year) and long‐term mortality (median: 5.6 years; interquartile range [IQR] 4.9‐6.5 years) were assessed. Multiple electrode aggregometry (MEA) was used to measure adenosine diphosphate (ADP)‐ and arachidonic acid (AA)‐induced platelet aggregation. Results: Type of P2Y12 inhibitor emerged as an independent predictor of long‐term mortality and MACE: patients treated with potent platelet inhibitors prasugrel or ticagrelor were at lower risk for long‐term mortality (adjusted hazard ratio [HR] = 0.44; 95% CI: 0.22‐0.92; P = .028) or MACE (adjusted HR = 0.38; 95% CI: 0.20‐0.73; P = .004) than those treated with clopidogrel independent from clinical risk factors. In contrast, the efficacy of clopidogrel decreased with increasing severity of ACS: platelet aggregation was 37% higher in patients with ST segment elevation myocardial infarction (STEMI) and 25% higher in patients with non‐ST elevation myocardial infarction (non‐STEMI) compared to patients with unstable angina ( P = .039). Patients with diabetes achieved less potent ADP‐ and AA‐induced platelet inhibition under clopidogrel, compared to patients without diabetes ( P = .045; P = .030, respectively). Conclusion: In the setting of ACS, treatment with ticagrelor or prasugrel reduced long‐term mortality and 1‐year MACE as compared to clopidogrel.